RELATED STUDY
Prospects for cannabinoid therapies in basal ganglia disorders.
Key Findings: The evidence reported so far supports that those cannabinoids having antioxidant properties and/or capability to activate CB2 receptors may represent promising therapeutic agents in HD and PD, thus deserving a prompt clinical evaluation.
Type of Study: Meta-analysis
Study Result: Positive
Study Location(s): Israel, Spain
Year of Pub: 2011
Cannabinoids Studied: Cannabidiol (CBD), Tetrahydrocannabinol (THC)
Phytocannabinoid Source: Not Applicable
Receptors Studied: CB1, CB2
Ligands Studied: Anti-inflammatory cytokines, Dopamine, GABA, Glutamate, Pro-inflammatory cytokines
